Written by StockNews.com
Gilead Sciences, Inc. (GILD) late Tuesday posted worse than expected first quarter earnings results and revenue, as sales of its HCV-focused drugs plummeted 40% from last year.
The Foster City, CA-based biopharmaceuticals giant reported Q1:
Looking ahead, GILD:
The company commented on its sizable cash position at the end of the quarter, along with its returns to shareholders, via press release:
As of March 31, 2017, Gilead had $34.0 billion of cash, cash equivalents and marketable securities compared to $32.4 billion as of December 31, 2016.
Cash flow from operating activities was $2.9 billion for the quarter.
During the first quarter of 2017, Gilead utilized $565 million on stock repurchases and paid cash dividends of $687 million.
Gilead Sciences, Inc. shares fell more than 2% in after-hours trading Tuesday. Year-to-date, GILD had declined -3.48% prior to today’s report, versus a +7.28% rise in the benchmark S&P 500 index during the same period.
GILD currently has a StockNews.com POWR Rating of C (Neutral) and is ranked #71 of 273 stocks in the Biotech category.
Leave A Comment